WCN26-6017 EFFECT OF PRESCRIBING SGLT2 INHIBITORS IN PATIENTS WITH CKD STAGES 4–5

Read full text Summarise with VIRAT
Authors: Daisuke Matsui, Daiki Aomura, Yuki Nakayama, Mayuka Nishigawara, Kosuke Yamaka, Makoto Harada, Koji Hashimoto, Yuji Kamijo
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Although sodium–glucose cotransporter 2 inhibitors (SGLT2i) are now widely used in chronic kidney disease (CKD), the efficacy and safety of initiating SGLT2i in advanced CKD remain uncertain. We investigated the potential benefits of SGLT2i initiation in patients with CKD stage G4–5.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Diabetes Treatment and Management Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104360–104360
Publication date
25 March 2026
Language
EN